Table 1 Clinical and metabolic patient variables (all of the patients and grouped according to macro-vascular involvement)
From: Macrovascular complication phenotypes in type 2 diabetic patients
Variables | All | NMVD (I) | NSCS (II) | CBVD (III) | CAD (IV) | PAD (V) | PVD (VI) | p differencesamong the groupsa |
|---|---|---|---|---|---|---|---|---|
N patients (%) | 1199 | 643 (53.6) | 69 (5.7) | 81 (6.8) | 89 (7.4) | 59 (4.9) | 258 (21.5) | _ |
Age (yy) | 67 (58–75) | 63 (55–72) | 66 (59–71) | 73 (66–79) | 65 (55–75) | 72 (65–76) | 73 (67–78) | I≠III,V,VI***, II≠III**,VI*** III≠IV***, IV≠V*,VI*** |
Sex %M | 49.5 | 45.3 | 39.1 | 37 | 58.4 | 61 | 61.2 | *** |
DM2 duration (yy) | 12 (6–20) | 10 (5–18) | 10 (5–15.5) | 12.5 (7–20) | 14 (6–20) | 20 (10–30) | 20 (10–28.3) | I≠V,VI***, II≠V,VI***, III≠VI*, IV≠VI** |
Weight (Kg) | 80 (69.5-92.7) | 81 (71.1-94.4) | 80.1 (67.3-93.8) | 74.6 (65.1-85.5) | 85.7 (74.4-98.6) | 75.2 (67–90) | 76.5 (65.4-87.8) | I≠III,VI**, III≠IV***, IV≠VI** |
BMI (Kg/m2) | 31.1 (27.6-35.5) | 31.5 (28.1-36.4) | 31.5 (26.5-36.6) | 29.7 (27.1-33.6) | 32.2 (27.6-37) | 30.3 (26.3-34.9) | 30 (26.3-33.8) | I≠VI**, IV≠VI* |
WC (cm) | 105 (97–118) | 106 (97–120) | 105.5 (94.3-119) | 102 (96–110.5) | 110 (98–120) | 103 (98–115.8) | 104 (97–116) | ns |
Smoking history % | 27.3 | 26.9 | 20.3 | 14.8 | 25.8 | 33.9 | 32.6 | *** |
SBP (mmHg) | 130 (120–140) | 130 (120–140) | 130 (120–140) | 130 (120–140) | 130 (120–140) | 130 (120–145) | 130 (120–140) | ns |
DBP (mmHg) | 80 (70–80) | 80 (70–80) | 80 (70–80) | 70 (70–80) | 80 (70–80) | 70 (70–80) | 80 (70–80) | ns |
TC (mg/dl) | 178 (151–210) | 183 (157–212) | 201 (175–221) | 176 (153–204) | 162 (132–193) | 179 (156–212) | 165 (135–196) | I≠IV,VI***, II≠IV,VI*** |
HDL-C (mg/dl) | 45 (38–55) | 47 (39–57) | 49 (39–58) | 47 (41–60) | 42 (35–50) | 45 (39–55) | 43 (35–52) | I≠IV*,I≠VI***, III≠IV,VI* |
LDL-C (mg/dl) | 102(77–131) | 105(83–133) | 121(99–144) | 101(76–129) | 82 (64–116) | 102(74–130) | 91 (70–123) | I≠IV,VI***, II≠IV,VI*** |
TG (mg/dl) | 124 (91–166) | 123 (91–161) | 125 (96–173) | 117 (82–149) | 126 (94–184) | 123 (90–170) | 130 (91–176) | ns |
HbA1c (%) | 8.1 (7–9.5) | 8.1 (7.1-9.7) | 8 (6.9-10.2) | 8.2 (6.8-9.5) | 8.1 (7.2-9.5) | 7.7 (6.8-9) | 8 (7–9.3) | ns |
FPG (mg/dl) | 174 (139–224) | 174 (138–230) | 177 (148–232) | 169 (138–213) | 182 (142–222) | 177 (140–218) | 174 (137–219) | ns |
2h-BG (mg/dl) | 201 (160–265) | 203 (160–270) | 219 (174–286) | 195 (160–232) | 205 (160–270) | 200 (167–239) | 200 (155–254) | ns |
∆BG (prandial) | 34 (−6-76) | 35 (−3-79) | 44 (14–81) | 39 (−8-88) | 38 (−1-61) | 31 (−22-58) | 22 (−16-69) | ns |
MetS % | 88 | 83.1 | 91.3 | 88.9 | 89 | 94.9 | 95.7 | *** |
3-4 MetS factors % | 61 | 55.7 | 62.3 | 64.2 | 73 | 69.5 | 66.7 | *** |
eGFR | 84 (65–101) | 89 (74–106) | 87 (61–100) | 79 (65–99) | 82 (57–103) | 66 (49–88) | 68 (50–88) | I≠III*,V,VI***, II≠V*, II≠VI**, IV≠VI* |
Albuminuria % | 25.9 | 24.3 | 21.9 | 25.3 | 31.8 | 33.3 | 27.2 | ns |
DR % | 37.3 | 28.6 | 33.3 | 40.7 | 38.2 | 78 | 49.2 | *** |
DN % | 49.7 | 39.0 | 42.0 | 53.1 | 43.8 | 88.1 | 70.5 | *** |
Statin users % | 65 | 55.4 | 69.6 | 70.4 | 76.4 | 81.4 | 78.7 | *** |
AH user % | 80.4 | 72.3 | 79.7 | 85.2 | 91 | 96.6 | 91.9 | *** |
OHA users % | 38.3 | 43.2 | 49.3 | 42 | 39.3 | 20.3 | 25.6 | *** |
OHA+BI users % | 13.6 | 16.5 | 11.6 | 8.6 | 10.1 | 10.1 | 10.5 | *** |
MDI users % | 48.1 | 48.1 | 39.1 | 49.4 | 50.6 | 69.3 | 63.9 | *** |